

# Edward A Levine

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6072830/publications.pdf>

Version: 2024-02-01

104  
papers

3,966  
citations

136950

32  
h-index

133252

59  
g-index

107  
all docs

107  
docs citations

107  
times ranked

3753  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Management of Colorectal Cancer with Peritoneal Dissemination: 30 Years of Experience at a Single Institution. <i>Journal of the American College of Surgeons</i> , 2022, 234, 546-556.	0.5	5
2	Timing of Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Recurrent Low-Grade Appendiceal Mucinous Neoplasms. <i>Annals of Surgical Oncology</i> , 2022, 29, 3422-3431.	1.5	5
3	An International Registry of Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>World Journal of Surgery</i> , 2022, 46, 1336-1343.	1.6	1
4	ASO Author Reflections: When is the Best Time to Perform Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for a Recurrent Low-Grade Appendiceal Mucinous Neoplasm?. <i>Annals of Surgical Oncology</i> , 2022, 29, 3432.	1.5	1
5	ASO Visual Abstract: Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Cancers with Peritoneal Metastasis—A 30-year Institutional Experience. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
6	Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for small bowel neuroendocrine tumors with peritoneal metastasis. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1626-1630.	1.0	5
7	ASO Visual Abstract: Timing of Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Recurrent Low-Grade Appendiceal Mucinous Neoplasms. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
8	Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Cancers with Peritoneal Metastasis: A 30-year Institutional Experience. <i>Annals of Surgical Oncology</i> , 2022, 29, 3436-3445.	1.5	11
9	ASO Author Reflections: Thirty Years of Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at Wake Forest University. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
10	Patient-Specific Sarcoma Organoids for Personalized Translational Research: Unification of the Operating Room with Rare Cancer Research and Clinical Implications. <i>Annals of Surgical Oncology</i> , 2022, 29, 7354-7367.	1.5	21
11	Cisplatin/5-Fluorouracil (5-FU) Versus Carboplatin/Paclitaxel Chemoradiotherapy as Definitive or Pre-Operative Treatment of Esophageal Cancer. <i>Cureus</i> , 2021, 13, e12574.	0.5	4
12	Cumulative GRAS Score as a Predictor of Survival After Resection for Adrenocortical Carcinoma: Analysis From the U.S. Adrenocortical Carcinoma Database. <i>Annals of Surgical Oncology</i> , 2021, 28, 6551-6561.	1.5	11
13	The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery. <i>JAMA Surgery</i> , 2021, 156, e206363.	4.3	74
14	Persistent opioid use after curative-intent hepatectomy for neoplastic disease. <i>Journal of Surgical Oncology</i> , 2021, 124, 301-307.	1.7	0
15	Diet Alters Entero-Mammary Signaling to Regulate the Breast Microbiome and Tumorigenesis. <i>Cancer Research</i> , 2021, 81, 3890-3904.	0.9	39
16	Patterns of peritoneal dissemination and response to systemic chemotherapy in common and rare peritoneal tumours treated by cytoreductive surgery: study protocol of a prospective, multicentre, observational study. <i>BMJ Open</i> , 2021, 11, e046819.	1.9	1
17	Organoid Platform in Preclinical Investigation of Personalized Immunotherapy Efficacy in Appendiceal Cancer: Feasibility Study. <i>Clinical Cancer Research</i> , 2021, 27, 5141-5150.	7.0	33
18	Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence. , 2021, 9, e003272.		6

#	ARTICLE	IF	CITATIONS
19	Evaluation of the Axillary Surgery Performed in Clinically Node-Positive Breast Cancer Patients Following Neoadjuvant Chemotherapy. <i>American Surgeon</i> , 2021, , 000313482110508.	0.8	0
20	Utility of hyperthermic intraperitoneal chemotherapy in cases of incomplete cytoreductive surgery. <i>Journal of Surgical Oncology</i> , 2021, , .	1.7	5
21	Outcomes After Adjuvant Hyperthermic Intraperitoneal Chemotherapy for High-Risk Primary Appendiceal Neoplasms After Complete Resection. <i>Annals of Surgical Oncology</i> , 2020, 27, 107-114.	1.5	4
22	Features of synchronous versus metachronous metastasectomy in adrenal cortical carcinoma: Analysis from the US adrenocortical carcinoma database. <i>Surgery</i> , 2020, 167, 352-357.	1.9	11
23	Role of Surgery for Metastatic Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 127-139.	1.5	19
24	Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study. <i>Annals of Surgical Oncology</i> , 2020, 27, 1956-1967.	1.5	91
25	ASO Author Reflections: Patient-Reported Outcomes of Mucinous Appendiceal Cancer Improve with Oxaliplatin HIPEC. <i>Annals of Surgical Oncology</i> , 2020, 27, 781-782.	1.5	1
26	Feasibility of low-cost accelerometers in measuring functional recovery after major oncologic surgery. <i>Journal of Surgical Oncology</i> , 2020, 121, 279-285.	1.7	13
27	Neoadjuvant Chemotherapy Shifts Breast Tumor Microbiota Populations to Regulate Drug Responsiveness and the Development of Metastasis. <i>Molecular Cancer Research</i> , 2020, 18, 130-139.	3.4	71
28	Is Sentinel Lymph Node Biopsy Necessary for Ductal Carcinoma In Situ Patients Undergoing Mastectomy?. <i>American Surgeon</i> , 2020, 86, 955-957.	0.8	4
29	Is Excisional Biopsy Needed for Pure FEA Diagnosed on a Core Biopsy?. <i>American Surgeon</i> , 2020, 86, 1088-1090.	0.8	7
30	ASO Author Reflections: Molecular Profiling Can Provide Personalized Clinical Guidance in the Management of Peritoneal Malignancies. <i>Annals of Surgical Oncology</i> , 2020, 27, 5024-5025.	1.5	2
31	Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma. <i>Case Reports in Urology</i> , 2020, 2020, 1-6.	0.3	3
32	Clinical Implications of Genetic Signatures in Appendiceal Cancer Patients with Incomplete Cytoreduction/HIPEC. <i>Annals of Surgical Oncology</i> , 2020, 27, 5016-5023.	1.5	10
33	Comparison of Tissue Molecular Biomarker Testing Turnaround Times and Concordance Between Standard of Care and the Biocartis Idylla Platform in Patients With Colorectal Cancer. <i>American Journal of Clinical Pathology</i> , 2020, 154, 266-276.	0.7	10
34	Personalized Identification of Optimal HIPEC Perfusion Protocol in Patient-Derived Tumor Organoid Platform. <i>Annals of Surgical Oncology</i> , 2020, 27, 4950-4960.	1.5	36
35	Hepatic arterial infusion chemotherapy for colorectal liver metastases revisited. <i>Hpb</i> , 2020, 22, 1265-1270.	0.3	2
36	Prognostic Molecular Classification of Appendiceal Mucinous Neoplasms Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2020, 27, 1439-1447.	1.5	11

#	ARTICLE	IF	CITATIONS
37	409â€¦A phase i trial of talimogene laherparepvec for the treatment of peritoneal surface malignancies (TEMPO)., 2020, , .		0
38	Iterative cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A multiâ€™institutional experience. Journal of Surgical Oncology, 2019, 119, 336-346.	1.7	31
39	Optimization of Tissue Microarrays from Banked Human Formalin-Fixed Paraffin Embedded Tissues in the Cancer Research Setting. Biopreservation and Biobanking, 2019, 17, 452-457.	1.0	3
40	Oncology Navigation Decreases Time to Treatment in Patients with Pancreatic Malignancy. Annals of Surgical Oncology, 2019, 26, 1512-1518.	1.5	16
41	&lt;p&gt;Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection and special considerations&lt;p&gt;. Cancer Management and Research, 2019, Volume 11, 4231-4241.	1.9	18
42	Dissecting intratumoral myeloid cell plasticity by single cell RNAâ€™seq. Cancer Medicine, 2019, 8, 3072-3085.	2.8	103
43	Effect of Negative Pressure Wound Therapy on Wound Complications Post-Pancreatectomy. American Surgeon, 2019, 85, 1-7.	0.8	17
44	Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study. Annals of Surgical Oncology, 2019, 26, 139-147.	1.5	69
45	Pelvic and Lower Gastrointestinal Tract Anatomical Characterization of the Average Male. Surgical Innovation, 2019, 26, 180-191.	0.9	1
46	Minimally Invasive Surgical Approaches for Peritoneal Surface Malignancy. Surgical Oncology Clinics of North America, 2019, 28, 161-176.	1.5	4
47	A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the US Adrenocortical Carcinoma Study Group. Annals of Surgical Oncology, 2018, 25, 520-527.	1.5	15
48	Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases From a Small Bowel Adenocarcinoma: Multi-Institutional Experience. Annals of Surgical Oncology, 2018, 25, 1184-1192.	1.5	30
49	Techniques for Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology, 2018, 25, 2152-2158.	1.5	15
50	A Multicenter Randomized Trial to Evaluate Hematologic Toxicities after Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin or Mitomycin in Patients with Appendiceal Tumors. Journal of the American College of Surgeons, 2018, 226, 434-443.	0.5	72
51	PCI is Not Predictive of Survival After Complete CRS/HIPEC in Peritoneal Dissemination from High-Grade Appendiceal Primaries. Annals of Surgical Oncology, 2018, 25, 674-678.	1.5	34
52	Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry. Annals of Surgical Oncology, 2018, 25, 667-673.	1.5	25
53	Re: The American Society of Peritoneal Surface Malignancies Multiâ€™institution Evaluation of 1,051 Advanced Ovarian Cancer Patients Undergoing Cytoreductive Surgery and HIPEC: An Introduction of the Peritoneal Surface Disease Severity Score. <i>Journal of Surgical Oncology</i> 2016;114(7):779â€™784.. Journal of Surgical Oncology, 2018, 118, 720-720.	1.7	1
54	Peritoneal Carcinomatosis of Urachus Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An International Registry of 36 Patients. Annals of Surgical Oncology, 2018, 25, 1094-1100.	1.5	14

#	ARTICLE	IF	CITATIONS
55	Analysis of recurrence after the resection of pancreatic neuroendocrine tumors. <i>Journal of Surgical Oncology</i> , 2018, 118, 416-421.	1.7	18
56	The Role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Appendiceal Tumors and Colorectal Adenocarcinomas. <i>Clinics in Colon and Rectal Surgery</i> , 2018, 31, 288-294.	1.1	11
57	Peritoneal Metastases from Appendiceal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 551-561.	1.5	16
58	Role of Additional Organ Resection in Adrenocortical Carcinoma: Analysis of 167 Patients from the U.S. Adrenocortical Carcinoma Database. <i>Annals of Surgical Oncology</i> , 2018, 25, 2308-2315.	1.5	19
59	A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the U.S. Adrenocortical Carcinoma Study Group. <i>VideoEndocrinology</i> , 2018, 5, .	0.1	0
60	Curative Surgical Resection of Adrenocortical Carcinoma. <i>Annals of Surgery</i> , 2017, 265, 197-204.	4.2	38
61	Prognostic Factors and Significance of Gastrointestinal Leak After Cytoreductive Surgery (CRS) with Heated Intraperitoneal Chemotherapy (HIPEC). <i>Annals of Surgical Oncology</i> , 2017, 24, 890-897.	1.5	41
62	Phase II Randomized Trial of Negative-Pressure Wound Therapy to Decrease Surgical Site Infection in Patients Undergoing Laparotomy for Gastrointestinal, Pancreatic, and Peritoneal Surface Malignancies. <i>Journal of the American College of Surgeons</i> , 2017, 224, 726-737.	0.5	86
63	Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. <i>Journal of Hematology and Oncology</i> , 2017, 10, 100.	17.0	28
64	Frailty Correlates with Postoperative Mortality and Major Morbidity After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2017, 24, 3825-3830.	1.5	15
65	Outcomes of Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients Older than 70 Years; Survival Benefit at Considerable Morbidity and Mortality: A Reply. <i>Annals of Surgical Oncology</i> , 2017, 24, 602-602.	1.5	5
66	Minimally Invasive Resection of Adrenocortical Carcinoma: a Multi-Institutional Study of 201 Patients. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 352-362.	1.7	27
67	Blood Transfusion and Survival for Resected Adrenocortical Carcinoma: A Study from the United States Adrenocortical Carcinoma Group. <i>American Surgeon</i> , 2017, 83, 761-768.	0.8	12
68	Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center. <i>Theranostics</i> , 2017, 7, 2914-2923.	10.0	31
69	Optimal extent of lymphadenectomy for gastric adenocarcinoma: A multi-institution study of the U.S. gastric cancer collaborative. <i>Journal of Surgical Oncology</i> , 2016, 113, 750-755.	1.7	33
70	Is Linitis Plastica a Contraindication for Surgical Resection: A Multi-Institution Study of the U.S. Gastric Cancer Collaborative. <i>Annals of Surgical Oncology</i> , 2016, 23, 1203-1211.	1.5	33
71	Outcomes after resection of cortisol-secreting adrenocortical carcinoma. <i>American Journal of Surgery</i> , 2016, 211, 1106-1113.	1.8	42
72	Quality-of-Life Evaluation After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2016, 23, 772-783.	1.5	44

#	ARTICLE	IF	CITATIONS
73	Actual 10-year survivors following resection of adrenocortical carcinoma. <i>Journal of Surgical Oncology</i> , 2016, 114, 971-976.	1.7	36
74	The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score. <i>Journal of Surgical Oncology</i> , 2016, 114, 779-784.	1.7	21
75	Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group. <i>Journal of the American College of Surgeons</i> , 2016, 222, 480-490.	0.5	71
76	Incidence of Perioperative Complications Following Resection of Adrenocortical Carcinoma and Its Association with Long-Term Survival. <i>World Journal of Surgery</i> , 2016, 40, 706-714.	1.6	15
77	Prognostic Molecular Subtypes of Low-Grade Cancer of the Appendix. <i>Journal of the American College of Surgeons</i> , 2016, 222, 493-503.	0.5	44
78	Routine Admission to Intensive Care Unit After Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy: Not Always a Requirement. <i>Annals of Surgical Oncology</i> , 2016, 23, 1486-1495.	1.5	29
79	Nomograms to Predict Recurrence-Free and Overall Survival After Curative Resection of Adrenocortical Carcinoma. <i>JAMA Surgery</i> , 2016, 151, 365.	4.3	102
80	Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes. <i>Annals of Surgical Oncology</i> , 2016, 23, 134-141.	1.5	76
81	Curative Resection of Adrenocortical Carcinoma: Rates and Patterns of Postoperative Recurrence. <i>Annals of Surgical Oncology</i> , 2016, 23, 126-133.	1.5	42
82	Conditional Survival After Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Low- and High-Grade Appendiceal Primaries. <i>Annals of Surgical Oncology</i> , 2016, 23, 534-538.	1.5	6
83	Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 3-9.	1.4	14
84	Bile duct surgery in the treatment of hepatobiliary and gallbladder malignancies: effects of hepatic and vascular resection on outcomes. <i>Hpb</i> , 2015, 17, 1066-1073.	0.3	3
85	Neutrophil-lymphocyte and platelet-lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma. <i>Journal of Surgical Oncology</i> , 2015, 112, 164-172.	1.7	36
86	Incidence and Risk Factors Associated with Readmission After Surgical Treatment for Adrenocortical Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 2154-2161.	1.7	2
87	Appendiceal goblet cell carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>Journal of Surgical Research</i> , 2015, 196, 229-234.	1.6	25
88	Changing Pattern in Malignant Mesothelioma Survival. <i>Translational Oncology</i> , 2015, 8, 35-39.	3.7	40
89	Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>Journal of Surgical Oncology</i> , 2014, 109, 740-745.	1.7	75
90	Outcomes with cytoreductive surgery and HIPEC for peritoneal metastasis. <i>Journal of Surgical Oncology</i> , 2014, 110, 575-584.	1.7	44

#	ARTICLE	IF	CITATIONS
91	Efficacy of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in the Management of Malignant Ascites. <i>Annals of Surgical Oncology</i> , 2014, 21, 1474-1479.	1.5	81
92	Significance of signet ring cells in high-grade mucinous adenocarcinoma of the peritoneum from appendiceal origin. <i>Human Pathology</i> , 2014, 45, 1597-1604.	2.0	40
93	Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy: Experience with 1,000 Patients. <i>Journal of the American College of Surgeons</i> , 2014, 218, 573-585.	0.5	221
94	Surgical management of colorectal cancer metastases to the liver: multimodality approach and a single institutional experience. <i>Colorectal Cancer</i> , 2013, 2, 73-88.	0.8	9
95	Optimal Timing of Systemic Therapy in Resectable Colorectal Liver Metastases. <i>American Surgeon</i> , 2013, 79, 414-421.	0.8	4
96	Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Journal of Clinical Oncology</i> , 2012, 30, 2449-2456.	1.6	873
97	Peritoneal Carcinomatosis: Cytoreductive Surgery and HIPEC—Overview and Basics. <i>Cancer Investigation</i> , 2012, 30, 209-224.	1.3	84
98	Use of FDG-PET Imaging for Patients with Disseminated Cancer of the Appendix. <i>American Surgeon</i> , 2010, 76, 1338-1344.	0.8	17
99	Does Shave Biopsy Accurately Predict the Final Breslow Depth of Primary Cutaneous Melanoma?. <i>American Surgeon</i> , 2009, 75, 369-373.	0.8	23
100	Intraoperative Imprint Cytology for Evaluation of Sentinel Lymph Nodes from Merkel Cell Carcinoma. <i>American Surgeon</i> , 2009, 75, 615-619.	0.8	6
101	Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Surface Malignancy: Experience with 501 Procedures. <i>Journal of the American College of Surgeons</i> , 2007, 204, 943-953.	0.5	187
102	Appendiceal Neoplasms With Peritoneal Dissemination: Outcomes After Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy. <i>Annals of Surgical Oncology</i> , 2006, 13, 624-634.	1.5	147
103	Positron Emission Mammography: Initial Clinical Results. <i>Annals of Surgical Oncology</i> , 2003, 10, 86-91.	1.5	73
104	Prognostic factors in soft tissue sarcoma. , 1999, 17, 23-32.		36